Onartuzumab

Drug Overview

Onartuzumab (also known by its developmental code MetMAb or PRO143913) is an investigational, recombinant, humanized monoclonal antibody designed to target the c-Met receptor (also known as Hepatocyte Growth Factor Receptor or HGFR). It is a unique, monovalent (one-armed) antibody engineered to inhibit the signaling pathways that drive tumor cell growth, survival, and metastasis.

In the clinical landscape of March 2026, onartuzumab is recognized as a pioneering attempt to target the “Met” pathway in oncology. Developed by Genentech/Roche, it was specifically designed to overcome a common problem with earlier Met-targeting antibodies: “agonism.” While traditional two-armed antibodies often accidentally activated the receptor they were meant to block, onartuzumab’s “one-armed” design ensures that it only inhibits the receptor, preventing the cancer from receiving growth signals from its primary fuel source, Hepatocyte Growth Factor (HGF).

• Generic Name: Onartuzumab.
• Code Name: MetMAb; PRO143913.
• Drug Class: c-Met Antagonist; Monoclonal Antibody.
• Mechanism: Monovalent binding to the extracellular domain of the c-Met receptor to block HGF-mediated signaling.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, onartuzumab is not FDA-approved. Following a major Phase 3 trial (the METLung study) that failed to meet its primary endpoints in 2014, the drug’s development was largely deprioritized, though it remains a subject of academic research and specialized clinical studies for “Met-high” tumors.

What Is It and How Does It Work? (Mechanism of Action)

Onartuzumab works by acting as a “molecular shield” that prevents a tumor from receiving its “marching orders” for growth.

1. The c-Met/HGF Pathway

The c-Met receptor is a protein found on the surface of many cells. When its partner molecule, HGF, binds to it, the receptor sends signals into the cell to divide, move, and resist death. In many cancers (like lung, gastric, and breast cancer), this pathway is overactive, either because there is too much c-Met or too much HGF.

2. The Monovalent (One-Armed) Advantage

Most antibodies have two “arms” (Fab regions). When a two-armed antibody binds to two c-Met receptors at once, it can accidentally push them together, which actually activates them—this is called “agonism.”

• The Solution: Onartuzumab was engineered with only one arm.
• The Result: It binds to a single c-Met receptor in a way that physically blocks HGF from attaching, without ever accidentally triggering the receptor’s growth signals.

3. Inhibition of Metastasis and Angiogenesis

By shutting down the c-Met engine, onartuzumab helps to:

• Stop Migration: Prevent cancer cells from breaking away from the original tumor to spread to other organs (metastasis).
• Starve the Tumor: Block the signals that tell the body to grow new blood vessels (angiogenesis) to feed the tumor.

Clinical Indications and Research Status (2026)

Onartuzumab has been studied across several “Met-driven” malignancies, with a focus on identifying the right biomarkers for success.

• Non-Small Cell Lung Cancer (NSCLC): The most extensive area of research. While the Phase 3 METLung trial failed in a broad population, subsequent analysis in 2024–2025 has looked at whether a very specific group of “Met-amplified” patients might still benefit.
• Gastric and Gastroesophageal Junction Cancer: Studied in the METGAST trial. Researchers are investigating if onartuzumab can be combined with chemotherapy to treat tumors that overexpress the Met protein.
• Metastatic Colorectal Cancer: Evaluated in combination with bevacizumab and chemotherapy to see if dual-targeting of vessels and growth receptors provides better control.
• Triple-Negative Breast Cancer (TNBC): Investigated for its ability to overcome the aggressive nature of Met-positive TNBC.

Dosage and Administration Protocols

As an investigational drug, onartuzumab dosing is strictly managed within clinical trial protocols (such as the OAM4971g study).

Safety Profile and Side Effects

The side effects of onartuzumab are unique among monoclonal antibodies, particularly regarding fluid balance in the body.

1. Peripheral Edema (The Most Common Side Effect)

The c-Met pathway is involved in how the body regulates fluid in tissues. Blocking it can cause:

• Symptoms: Swelling of the legs, ankles, and sometimes the face.
• Management: This is reported in nearly 30–40% of patients and is usually managed with diuretics (water pills).

2. Gastrointestinal and Skin Issues

• Nausea and Vomiting: Usually mild to moderate.
• Rash: Especially when combined with EGFR inhibitors like erlotinib.
• Fatigue: General systemic tiredness.

3. Serious Risks:

• Hypoalbuminemia: Low levels of the protein albumin in the blood, which can worsen swelling.
• Infusion-Related Reactions: Fever, chills, or shortness of breath during the IV drip.
• Pulmonary Embolism: A rare but serious risk of blood clots in the lungs noted in some early trials.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, onartuzumab is used to study “Tissue Repair Signaling.” Because the c-Met/HGF pathway is the primary signal for liver and skin regeneration, researchers are using onartuzumab to understand how to “turn off” this pathway in cancer without damaging the body’s natural ability to heal. In 2026, there is also intense focus on “Met-Resistance Biomarkers.” Scientists are using liquid biopsies to find “Met mutations” that appear when a patient becomes resistant to other drugs, exploring if onartuzumab can be used as a “rescue therapy” for these specific patients.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Met Testing (Biomarker): Essential. Most 2026 research protocols require Immunohistochemistry (IHC) or FISH testing to prove the tumor is “Met-positive” before the drug is administered.
• Baseline Fluid Check: Monitoring weight and leg swelling before starting.

“Do’s and Don’ts” List:

• DO monitor your weight daily; a sudden gain of 3–5 pounds in a week could be an early sign of the edema (swelling) side effect.
• DO wear compression stockings if you notice mild leg swelling, as directed by your care team.
• DON’T ignore a “new cough” or “sudden shortness of breath,” which could be signs of rare but serious lung or clot issues.
• DON’T take any new over-the-counter medications for “water retention” without consulting your oncologist, as they may interfere with your lab results.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Onartuzumab (MetMAb) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is limited exclusively to registered clinical trials and compassionate use programs. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.